The objective of the present research study was to develop a buccal mucoadhesive patch containing Glipizide. Glipizide is a 2nd generation sulfonyl ureas for type 2 Diabetes. MOA of it , Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Glipizide has shorter half life (5-6 hrs), high first pass metabolism and poor bioavailability (30%). So, in order to improve the bioavailabilty and therapeutic efficacy. Glipizide was delivered through buccal delivery system using mucoadhesive polymer like Hydroxy methyl ethyl cellulose (HPMC), Carbopol 940, and Sodium Alginate. HPMC K15 was as hydrophilic polymer to modify the release of Glipizide. Buccal Patch were characterized for number of parameters like physical appearance, surface texture, weight uniformity, thickness, folding enurance, drug content uniformity, surface pH, swelling index, in vitro residence time, mucoadheive strength, in vitro release, permeation studies. On the basis of above mentioned characterization studies buccal mucoadhesive patch containing Sodium Alginate and Carbopol 940 was optimized. Stability studies of the optimized batch suggested that there was no significant change in surface ph, drug content, bioadhesion property, swelling behaviour of the patches after storage. FTIR studies revealed that, there was no incompatibility of the drug with the excipients used.
Loading....